The use of nucleotides in diseases of the peripheral nervous system

Authors

  • N.I. Fister Uzhhorod National University, Uzhhorod, Ukraine
  • M.M. Oros Uzhhorod National University, Uzhhorod, Ukraine

DOI:

https://doi.org/10.22141/2224-0713.16.8.2020.221958

Keywords:

peripheral nervous system, nucleotides, uridine monophosphate, cyanocobalamin, folic acid, peripheral neuropathic pain

Abstract

Peripheral neuropathy (PN) is a common condition with a preva-lence of approximately 8 % in the elderly. Neuropathic pain is significant in the general population and affects more than half of all patients with PN. The pathophysiology of PN is characterized by lesions of myelin-producing Schwann cells in peripheral nerves. Regeneration/protection of the myelin sheath after nerve damage is the main element of recovery in PN. The problem of neuropathic pain is becoming increasingly important for clinicians of various profiles due to the significant spread of pathology and difficulties in achieving a persistent therapeutic effect. Despite the large number of pharmacological drugs recommended for the management of patients with neuropathic pain, the choice of the optimal treatment regimen often causes difficulties for clinicians. Over the last decade, a group of so-called nucleotides has been used quite actively in medical practice. Additional information about the effects of this group of drugs is accumulated, and there is a gradual transformation, including their composition. Thus, recently the attention of researchers has been devoted to studying the effectiveness of the combination “uridine monophosphate + vitamin B12 (cyanocobalamin) + folic acid”, which is characterized by a fairly high safety profile and good regenerative potential. The objective of this article is to highlight the mechanisms of action and results of clinical use of this combination.

References

Аattal N., Cruccu G., Baron R. et al. European Federation of Neurological Societies: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol. 2010. 17. e1113-e1188.

Scholz J., Finnerup N.B., Attal N. et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019. Vol. 160. № 1. P. 53-59.

Szok D., Tajti J., Nyári A., Vécsei L. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav. Neurol. 2019. Vol. 2019. Article ID 8685954.

Negrão L., Almeida P., Alcino S. et al. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag. 2014. Vol. 4. № 3. P. 191-196.

Finnerup N.B., Attal N. Pharmacotherapy of neuropathic pain: time to rewrite the rulebook. Pain Manag. 2016. 6(1). 1–3.

Finnerup N.B., Otto M., McQuay H.J. et al. Algorithm for neuropathic pain treatment — an evidence based proposal. Pain. 2005. 118(3). 289-305.

Lauretti G.C., Оmals M., Pereira A.C. et al. Clinical evaluation of the analgesic effect of the cytidine-uridine-hydroxocobalamin complex as a coadjuvant in the treatment of chronic neuropathic low back pain. Column. 2004. 3(2). 73-76.

Мartinez V., Аttal N., Bouhassira D. et al. Chronic neuropathic pain: diagnosis, evaluation and treatment in outpatient services. Guidelines for clinical practice of the French Society for the Study and Treatment of Pain. Douleur analg. 2010. 23. 51-66.

Мüller D. Treatment of neuropathic pain syndromes. Results of an open study of the efficacy of a preparation based on pyrimidine nucleotides. Munich: Medien und Medizin Verlagsgesellschaft mbH&Co, 2002.

Okada M., Nakagawa T., Minami M., Satoh M. Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model rats. J. Pharmacol. Exp. Ther. 2002. Vol. 303. № 1. P. 66-73.

Negrão L., Аlmeida P., Alcino S. et al. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag. 2014. 4(3). 191-196. doi: 10.2217/pmt.14.10.

Suezawa Y., Jacob H.A. Percutaneous nucleotomy. An alternative to spinal surgery. Arch. Orthop. Trauma Surg. 1986. Vol. 105. № 5. P. 287-295.

Sheki A.A., Hamdan F.B. The role of different neurophysiological tests in the differential diagnosis of diabetic axonal neuropathy and lumbosacral radiculopathy. Neurosciences (Riyadh). 2009. Vol. 14. № 1. P. 25-30.

Manole E., Bastian A., Neagu M. et al. Schwann Cell Plasticity in Peripheral Nerve Regeneration after Injury. 2020. https://www.intechopen.com.

Yonezawa T., Onomura T., Kosaka R. et al. The system and procedures of percutaneous intradiscal laser nucleotomy. Spine (Phila. Pa 1976). 1990. Vol. 15. № 11. P. 1175-1185.

Downloads

Published

2020-11-01

Issue

Vol. 16 No. 8 (2020)

Section

To practicing Neurologist

License

Copyright (c) 2021 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.